News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
516,073 Results
Type
Article (39182)
Company Profile (248)
Press Release (476633)
Multimedia
Podcasts (125)
Webinars (14)
Section
Business (137571)
Career Advice (1019)
Deals (24734)
Drug Delivery (114)
Drug Development (68498)
Employer Resources (97)
FDA (13466)
Job Trends (10497)
News (244677)
Policy (22016)
Tag
2027 BioMidwest Elite (2)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2085)
Academic (1)
Accelerated approval (52)
Adcomms (31)
Allergies (132)
Alliances (35804)
ALS (203)
Alzheimer's disease (1616)
Antibody-drug conjugate (ADC) (483)
Approvals (13803)
Artificial intelligence (634)
Autoimmune disease (316)
Automation (52)
Bankruptcy (187)
Best Places to Work (8859)
BIOSECURE Act (16)
Biosimilars (189)
Biotechnology (187)
Bladder cancer (198)
Brain cancer (78)
Breast cancer (734)
Cancer (5806)
Cardiovascular disease (473)
Career advice (875)
Career pathing (21)
CAR-T (369)
CDC (29)
Celiac Disease (3)
Cell therapy (1025)
Cervical cancer (41)
Clinical research (60432)
Collaboration (2029)
Company closure (5)
Compensation (955)
Complete response letters (82)
COVID-19 (2121)
CRISPR (120)
C-suite (1021)
Cystic fibrosis (162)
Data (7735)
Decentralized trials (1)
Denatured (22)
Depression (166)
Dermatology (85)
Diabetes (536)
Diagnostics (5431)
Digital health (40)
Diversity (5)
Diversity, equity & inclusion (28)
Drug discovery (328)
Drug pricing (146)
Drug shortages (28)
Duchenne muscular dystrophy (306)
Earnings (61573)
Editorial (57)
Employer branding (15)
Employer resources (89)
Events (77931)
Executive appointments (916)
FDA (16915)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (18)
Frontotemporal dementia (33)
Funding (1601)
Gene editing (266)
Generative AI (64)
Gene therapy (835)
GLP-1 (944)
Government (3051)
Grass and pollen (5)
Guidances (391)
Healthcare (14110)
HIV (77)
Huntington's disease (58)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (102)
Immunology and inflammation (273)
Immuno-oncology (101)
Indications (186)
Infectious disease (2404)
Inflammatory bowel disease (210)
Inflation Reduction Act (11)
Influenza (105)
Intellectual property (261)
Interviews (169)
IPO (12599)
IRA (29)
Job creations (2022)
Job search strategy (730)
JPM (60)
Kidney cancer (19)
Labor market (53)
Layoffs (469)
Leadership (27)
Legal (4678)
Liver cancer (90)
Longevity (31)
Lung cancer (760)
Lymphoma (434)
Machine learning (56)
Management (28)
Manufacturing (936)
MASH (196)
Medical device (8914)
Medtech (8996)
Mergers & acquisitions (13263)
Metabolic disorders (1434)
mRNA (205)
Multiple sclerosis (183)
NASH (18)
Neurodegenerative disease (433)
Neuropsychiatric disorders (107)
Neuroscience (3121)
Neurotech (1)
NextGen: Class of 2026 (4238)
Non-profit (2982)
Now hiring (35)
Obesity (674)
Opinion (264)
Ovarian cancer (220)
Pain (237)
Pancreatic cancer (284)
Parkinson's disease (368)
Partnered (27)
Patents (519)
Patient recruitment (674)
Peanut (51)
People (40858)
Pharmaceutical (44)
Pharmacy benefit managers (24)
Phase 1 (19130)
Phase 2 (26669)
Phase 3 (20120)
Pipeline (8508)
Policy (234)
Postmarket research (1993)
Preclinical (7891)
Press Release (71)
Prostate cancer (305)
Psychedelics (63)
Radiopharmaceuticals (328)
Rare diseases (1165)
Real estate (3307)
Recruiting (38)
Regulatory (19189)
Reports (34)
Research institute (2136)
Resumes & cover letters (171)
Rett syndrome (38)
RNA editing (27)
RSV (71)
Schizophrenia (173)
Series A (285)
Series B (203)
Service/supplier (6)
Sickle cell disease (121)
Special edition (21)
Spinal muscular atrophy (182)
Sponsored (43)
Startups (2707)
State (1)
Stomach cancer (18)
Supply chain (97)
Tariffs (58)
The Weekly (101)
Vaccines (859)
Venture capital (97)
Weight loss (428)
Women's health (93)
Worklife (8)
Date
Today (121)
Last 7 days (574)
Last 30 days (3132)
Last 365 days (26941)
2026 (12018)
2025 (26649)
2024 (30194)
2023 (33561)
2022 (42333)
2021 (45264)
2020 (41229)
2019 (32441)
2018 (24627)
2017 (24750)
2016 (22786)
2015 (26396)
2014 (18986)
2013 (22452)
2012 (15690)
2011 (16122)
2010 (14677)
Location
Africa (531)
Alabama (66)
Alaska (5)
Arizona (212)
Arkansas (8)
Asia (31517)
Australia (5556)
California (11690)
Canada (3158)
China (1324)
Colorado (437)
Connecticut (516)
Delaware (353)
Europe (73916)
Florida (1747)
Georgia (344)
Hawaii (3)
Idaho (43)
Illinois (838)
India (88)
Indiana (506)
Iowa (19)
Japan (500)
Kansas (106)
Kentucky (44)
Louisiana (37)
Maine (52)
Maryland (1354)
Massachusetts (8718)
Michigan (301)
Minnesota (552)
Mississippi (6)
Missouri (139)
Montana (22)
Nebraska (14)
Nevada (115)
New Hampshire (62)
New Jersey (3199)
New Mexico (25)
New York (3055)
North Carolina (1497)
North Dakota (10)
Northern California (5962)
Ohio (324)
Oklahoma (10)
Oregon (30)
Pennsylvania (2223)
Puerto Rico (21)
Rhode Island (35)
South America (690)
South Carolina (44)
South Dakota (2)
Southern California (4554)
Tennessee (127)
Texas (1801)
United States (40894)
Utah (354)
Vermont (1)
Virginia (267)
Washington D.C. (60)
Washington State (964)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
516,073 Results for "sio gene therapies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
4 spaces primed for the next wave of gene therapies
The recent approval of Regeneron’s Otarmeni underscores the maturation of gene therapies across a range of diseases. Here,
BioSpace
reviews genetic medicines in development for the central nervous system, retinal, cardiac and neuromuscular diseases.
May 18, 2026
·
8 min read
·
Andrea Park
Opinion
Gene therapy’s evidence problem—lessons from recent FDA decisions
Comprehending the spate of recent rejections in the cell and gene therapy space may require looking no further than early-stage clinical trials of candidates from REGENXBIO, Excision BioTherapeutics and Intellia Therapeutics.
May 4, 2026
·
6 min read
·
Jenna DiRito
Funding
Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases
George Church’s Rejuvenate Bio is turning to social networks to help fund its work on one-time gene therapies targeting chronic diseases and root causes of aging.
April 27, 2026
·
2 min read
·
Tristan Manalac
gene editing
Gene therapy leaders aim to help more Baby KJs with novel regulatory models
As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” session focused on the need to expedite more bespoke gene editing treatments like the one that saved young KJ Muldoon.
April 27, 2026
·
5 min read
·
Heather McKenzie
Gene therapy
FDA approval of Regeneron’s hearing loss gene therapy breaks barriers
Approved Thursday via the FDA’s Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for hearing loss—and the first treatment to target an underlying cause of the condition.
April 23, 2026
·
4 min read
·
Heather McKenzie
Gene therapy
Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality
Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential billion-dollar market and banking on local delivery and the small amount of drug required to overcome key safety concerns.
March 23, 2026
·
7 min read
·
Tristan Manalac
Manufacturing
Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032
Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.
March 10, 2026
·
3 min read
·
Nick Paul Taylor
Press Releases
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
February 5, 2026
·
10 min read
Gene editing
Pfizer Advances Beam’s Gene Editor After Pulling Hemophilia Gene Therapy
Pfizer will be responsible for all global clinical and regulatory activities for Beam Therapeutics’ liver-directed gene editor.
February 26, 2026
·
1 min read
·
Tristan Manalac
Sickle cell disease
Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
February 23, 2026
·
6 min read
·
Heather McKenzie
1 of 51,608
Next
